The complement cascade produces three major outcomes: it tags pathogens for destruction (opsonization), it triggers inflammation to recruit immune cells, and it directly kills certain bacteria by punching holes in their membranes. These three functions work together as one of the body’s fastest defenses against infection, operating entirely without the slower, learned responses of the adaptive immune system.
Opsonization: Tagging Pathogens for Destruction
The most important outcome of the complement cascade is opsonization. When the cascade activates, it produces a protein fragment called C3b that physically attaches to the surface of a pathogen. C3b binds to multiple sites on the microbe’s outer surface, essentially coating it. Immune cells like macrophages and neutrophils carry receptors that recognize C3b, so when they encounter a pathogen covered in these tags, they engulf and destroy it far more efficiently than they would an untagged invader.
Think of it like putting a bright sticker on something you want picked up. Without the sticker, immune cells might still find the pathogen, but the process is slower and less reliable. With C3b coating, phagocytosis (the process of an immune cell swallowing a pathogen) increases dramatically. This tagging function is considered the single most important protective outcome of the entire complement system.
Inflammation and Immune Cell Recruitment
As the complement cascade proceeds, it also generates small protein fragments called C3a and C5a, sometimes referred to as anaphylatoxins. These fragments act as chemical alarm signals that produce local inflammation and draw additional immune cells to the site of infection.
C5a is especially potent. It attracts neutrophils, eosinophils, basophils, and monocytes to wherever complement activation is happening. C3a overlaps somewhat but has its own profile: it attracts eosinophils and mast cells but does not recruit neutrophils. Both C3a and C5a trigger mast cells in the skin and tissues to release histamine, which causes blood vessels to dilate and become more permeable. This is what produces the redness, swelling, and warmth you associate with inflammation. That increased blood flow brings even more immune cells to the area, amplifying the response.
The inflammatory outcome works hand in hand with opsonization. The cascade tags the pathogen for eating while simultaneously calling in more cells to do the eating.
Direct Killing Through the Membrane Attack Complex
The third outcome is the most dramatic: the complement cascade can kill certain pathogens outright. The final proteins in the cascade (C5b, C6, C7, C8, and C9) assemble on the surface of a target cell to form a structure called the membrane attack complex, or MAC. This complex creates a physical pore through the cell membrane, with an internal diameter of about 5 nanometers.
C9 is the key building block. A single C9 molecule binds first, then additional C9 molecules polymerize onto it, with up to 16 molecules stacking together to form a ring-shaped channel. The pore disrupts the cell’s ability to maintain its internal environment. Water and ions rush through, and in the case of red blood cells, a single pore is enough to cause lysis through osmotic swelling.
This killing mechanism works best against Gram-negative bacteria, which have a thin outer wall. Gram-positive bacteria, by contrast, are naturally resistant to the MAC because they have a thick outer layer of peptidoglycan that prevents the pore from inserting correctly. This is why opsonization and inflammation are generally considered more important than direct lysis for overall immune defense.
Three Pathways, Same Outcomes
The complement cascade can be triggered through three different starting points, but all three converge on the same set of outcomes described above. The classical pathway starts when antibodies bound to a pathogen activate the first complement protein, C1. The lectin pathway kicks in when a blood protein called mannose-binding lectin recognizes specific sugar patterns on bacterial or fungal surfaces. The alternative pathway is always ticking along at a low level: a small amount of C3 spontaneously breaks down in the blood, and if the fragments land on a microbial surface (rather than a protected host cell), the cascade amplifies.
Regardless of which pathway initiates the process, all three produce C3b for opsonization, C3a and C5a for inflammation, and the C5b-9 membrane attack complex for direct killing.
How Your Cells Protect Themselves
Because complement proteins circulate throughout the blood, the body needs a way to prevent them from attacking its own cells. Human cells carry surface proteins that act as brakes on the cascade. One, called decay-accelerating factor (DAF), breaks apart the enzyme complexes that drive complement activation, stopping the cascade early. Another, called CD59, specifically blocks the final step of MAC assembly by preventing C9 from joining the complex.
DAF appears to be the more critical of the two under normal conditions. In animal studies, mice lacking DAF developed significantly more inflammatory kidney disease when the complement system was activated, while mice lacking only CD59 showed no difference from normal mice. However, CD59 becomes essential when complement activation is intense enough to overwhelm the earlier brakes.
What Happens When Complement Goes Wrong
Because C3 sits at the convergence point of all three pathways, a genetic deficiency in C3 has severe consequences. People born without functional C3 typically develop recurrent, serious infections starting shortly after birth. About 20% also develop autoimmune disease or kidney inflammation, since one of complement’s quieter jobs is helping clear immune complexes (clumps of antibodies and their targets) from the bloodstream. Without C3, those complexes accumulate and damage tissues.
On the other end of the spectrum, overactive complement can attack the body’s own cells. Several approved medications now target specific complement proteins to treat these conditions. One class blocks C5, the protein that drives both inflammation (through C5a) and membrane attack complex formation. These drugs treat conditions like paroxysmal nocturnal hemoglobinuria, where red blood cells lack the protective surface proteins and get destroyed by the patient’s own complement system. Other drugs target C3 or C1 for different diseases where complement-driven damage is the core problem.